Latest ACRP-CP Practice Tests

Get Complete pool of questions with Premium PDF and Test Engine

Exam Code : ACRP-CP
Exam Name : Certified Clinical Research Professional - Certified Professional
Vendor Name : "Nursing"






Question: 1


Which of the following is an example of a double-blind study design?


  1. Investigators are unaware of the treatment assignments, but participants are aware.

  2. Participants are unaware of the treatment assignments, but investigators are aware.

  3. Participants and investigators are aware of the treatment assignments.

  4. Participants and investigators are unaware of the treatment assignments.

    Answer: D


Explanation: In a double-blind study design, both the participants and the investigators are unaware of the treatment assignments. This design helps minimize biases and ensures the objectivity of the study outcomes. Blinding is particularly important when evaluating interventions to avoid any potential influence or bias due to the participants' or investigators' knowledge of the treatment assignments.



Question: 2


Which of the following is an example of an electronic data capture (EDC) system used in clinical trials?


  1. Oracle Clinical

  2. Paper case report forms (CRFs)

  3. Microsoft Excel

  4. Adobe Acrobat




Answer: A


Explanation: Oracle Clinical is an example of an electronic data capture (EDC) system commonly used in clinical trials. EDC systems are software applications designed to collect, manage, and store clinical trial data electronically. These systems streamline data collection and facilitate data cleaning, analysis, and reporting. Unlike paper case report forms (CRFs) or general-purpose software like Microsoft Excel or Adobe Acrobat, specialized EDC systems offer robust features and data validation capabilitiesQuestion 8:


Which of the following actions is NOT considered a part of study and site management in clinical research?


  1. Ensuring adequate training of site staff

  2. Monitoring study progress and data quality

  3. Managing participant recruitment and enrollment

  4. Conducting statistical analysis of study results

    Answer: D


Explanation: Conducting statistical analysis of study results is not typically considered a part of study and site management in clinical research. Study and site management involve activities such as ensuring adequate training of site staff, monitoring study progress and data quality, managing participant recruitment and enrollment, and overseeing compliance with the study protocol. Statistical analysis of study results is usually performed by biostatisticians or data analysts.



Question: 3


Which of the following is a key principle of Good Clinical Practice (GCP)?


  1. Maximizing sponsor's financial interests

  2. Protecting the rights and well-being of study participants

  3. Minimizing the use of informed consent

  4. Concealing potential risks from study participants

    Answer: B


Explanation: A key principle of Good Clinical Practice (GCP) is protecting the rights and well-being of study participants. GCP guidelines are designed to ensure that clinical trials are conducted ethically and that the rights, safety, and well-being of trial participants are protected. This includes obtaining informed consent, minimizing risks to participants, and maintaining confidentiality of participants' personal information.



Question: 4


Which regulatory authority is responsible for the approval of investigational new drugs (INDs) in the United States?


  1. European Medicines Agency (EMA)

  2. Pharmaceuticals and Medical Devices Agency (PMDA)

  3. Food and Drug Administration (FDA)

  4. Health Canada

    Answer: C


Explanation: The Food and Drug Administration (FDA) is the regulatory authority responsible for the approval of investigational new drugs (INDs) in the United States. The FDA plays a crucial role in ensuring the safety and efficacy of drugs and biologics before they can be marketed for general use. The FDA reviews the data provided by sponsors during the IND application process to determine whether the investigational product can proceed to clinical trials.



Question: 5

Which of the following is NOT a responsibility of a clinical research coordinator (CRC) during a clinical trial?


  1. Ensuring compliance with the protocol

  2. Analyzing and interpreting study data

  3. Obtaining informed consent from study participants

  4. Documenting and reporting adverse events




Answer: B



Explanation: Analyzing and interpreting study data is not typically a responsibility of a clinical research coordinator (CRC) during a clinical trial. The CRC's primary role is to ensure compliance with the study protocol, including participant recruitment, data collection, and documentation. Analyzing and interpreting study data is often performed by the study sponsor, data management personnel, biostatisticians, or other specialized roles.



Question: 6


Which of the following is an example of a serious adverse event (SAE) in a clinical trial?


  1. Mild headache

  2. Temporary skin rash

  3. Myocardial infarction

  4. Transient nausea

    Answer: C


Explanation: An SAE in a clinical trial refers to any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent

or significant disability/incapacity, or causes a congenital anomaly/birth defect. Among the options, myocardial infarction (heart attack) is a severe and potentially life-threatening event that qualifies as a serious adverse event.



Question: 7


Which of the following study designs is most appropriate for evaluating the effectiveness of a new drug compared to an existing standard of care?


  1. Case-control study

  2. Cross-sectional study

  3. Cohort study

  4. Randomized controlled trial

    Answer: D


Explanation: The most appropriate study design for evaluating the effectiveness of a new drug compared to an existing standard of care is a randomized controlled trial (RCT). RCTs are considered the gold standard for assessing the efficacy and safety of interventions. In an RCT, participants are randomly assigned to receive either the new drug or the standard of care, allowing for a direct comparison between the two groups.



Question: 8


Which of the following medications require close monitoring of digoxin levels when started?


  1. Loratadine

  2. Diphenhydramine

  3. Albuterol

  4. Ipratropium



Answer: C



Explanation: Digoxin levels need to be monitored closely when starting Albuterol. Albuterol, a bronchodilator commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD), can cause an increase in serum digoxin levels. This interaction could lead to digoxin toxicity, which can manifest as symptoms such as nausea, vomiting, visual disturbances, and cardiac arrhythmias. Therefore, it is important to closely monitor digoxin levels when initiating Albuterol therapy to ensure patient safety.